Stage IIB Prostate Cancer Clinical Trial
Official title:
A Prospective Investigation of Near Infrared Fluorescence Imaging of Pelvic Lymph Nodes Using Indocyanine Green on the da Vinci Surgical System During Radical Prostatectomy and Pelvic Lymphadenectomy for Localized Prostate Cancer
Verified date | February 2018 |
Source | City of Hope Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial studies diffuse optical imaging with indocyanine green solution in imaging pelvic lymph nodes in patients with stage II prostate cancer undergoing surgery. Indocyanine green solution is a special dye that can help doctors see the lymph nodes and blood vessels during surgery when visualized under diffuse optical imaging. Indocyanine green solution may improve the ability to detect lymph nodes and may lead to improved accuracy of lymph node removal.
Status | Completed |
Enrollment | 20 |
Est. completion date | February 7, 2018 |
Est. primary completion date | February 7, 2018 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Stage 2, intermediate to high risk (per D'Amico criteria) localized prostate cancer with a prostate gland size =< 100 grams - Intermediate risk: prostate specific antigen (PSA) between 10-20, Gleason grade 7, or clinical stage T2b - High risk: PSA > 20 , Gleason grade >= 8, or clinical stage >= T2c - Life expectancy of at least 10 years - Eastern Cooperative Oncology Group (ECOG) performance status =< 2 - The subject must be able to comply with the study procedures - All subjects must have the ability to understand and the willingness to sign a written informed consent Exclusion Criteria: - Subject has significant liver disease, cirrhosis or liver insufficiency with abnormal liver function tests, as total bilirubin > 1.5 x normal - Subject has significant liver disease, cirrhosis or liver insufficiency with abnormal liver function tests, as serum glutamic oxaloacetic transaminase (SGOT) > 2 x normal - Prior prostate surgery (i.e. transurethral resection of the prostate), or any prior abdominal or pelvic surgery, most specifically for surgeries that may have included any form of lymphadenectomy or anatomic changes - History of androgen deprivation therapy, any prior chemotherapy, or any prior radiation therapy to the pelvis - Subject has a previous history of adverse reaction or allergy to ICG, iodine, shellfish or iodine dyes - Subject in whom the use of x-ray dye or ICG is contraindicated including development of adverse events when previously or presently administered - Subject has any medical condition, which in the judgment of the investigator and/or designee makes the subject a poor candidate for the investigational procedure - The presence of medical conditions contraindicating general anesthesia or standard surgical approaches |
Country | Name | City | State |
---|---|---|---|
United States | City of Hope Medical Center | Duarte | California |
Lead Sponsor | Collaborator |
---|---|
City of Hope Medical Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intraoperative detection of fluorescence in pelvic lymphatic tissue by near-infrared imaging technology on the da Vinci Surgical System following direct injection of ICG into the prostate | The ability to image lymph nodes prior to dissection will be estimated using means and standard errors for all observations as well as stratified by dose level and other relevant patient characteristics. | At the time of surgery | |
Secondary | Quality of fluorescence as detected by near-infrared technology on the da Vinci Surgical System of lymphatic tissue at varying safe doses of ICG | Analyzed using means and standard errors for continuous data and generating frequencies and percentages for categorical data. The Kruskal Wallis test and chi-square test (or Fisher's exact test as appropriate) will be used to detect any apparent differences in continuous and categorical data, respectively. | At the time of surgery | |
Secondary | Lymph node yield | Analyzed using means and standard errors for continuous data and generating frequencies and percentages for categorical data. The Kruskal Wallis test and chi-square test (or Fisher's exact test as appropriate) will be used to detect any apparent differences in continuous and categorical data, respectively. | At the time of surgery | |
Secondary | Number of positive lymph nodes (nodes that contain cancer on final pathology) | Analyzed using means and standard errors for continuous data and generating frequencies and percentages for categorical data. The Kruskal Wallis test and chi-square test (or Fisher's exact test as appropriate) will be used to detect any apparent differences in continuous and categorical data, respectively. | At the time of surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02217709 -
Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer
|
Phase 2 | |
Completed |
NCT03233555 -
Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer
|
N/A | |
Completed |
NCT00103194 -
Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
|
Phase 2 | |
Completed |
NCT02250014 -
The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer
|
Phase 1 | |
Active, not recruiting |
NCT01655836 -
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
|
Phase 1 | |
Terminated |
NCT01340599 -
Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery
|
Phase 2 | |
Active, not recruiting |
NCT01823562 -
Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery
|
Phase 1 | |
Active, not recruiting |
NCT01923506 -
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
|
Phase 1 | |
Completed |
NCT01433913 -
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
|
Phase 2 | |
Completed |
NCT00589472 -
Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02176902 -
Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer
|
N/A | |
Completed |
NCT01731912 -
Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer
|
N/A | |
Completed |
NCT01656304 -
Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
|
Phase 2 | |
Recruiting |
NCT03880422 -
Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT02446366 -
Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery
|
N/A | |
Completed |
NCT02048150 -
Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer
|
Phase 1 | |
Withdrawn |
NCT01859689 -
Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer
|
Phase 2 | |
Withdrawn |
NCT01555632 -
Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy
|
N/A | |
Completed |
NCT00956163 -
Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer
|
Phase 0 | |
Completed |
NCT01023061 -
Abiraterone Acetate, Prednisone, and Leuprolide Acetate or Goserelin Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer
|
Phase 2 |